Another company gets FDA designation to treat depression with psilocybin

The Food and Drug Administration has granted the 'Breakthrough Therapy' designation to the treatment of major depression disorder (MDD) using psilocybin, the psychoactive compound found in many mushrooms collectively referred to as 'magic mushrooms.' The designation was granted to Usona Institute, enabling it to proceed with an investigation into psilocybin-based treatment for MDD. Psilocybin is a psychedelic that remains illegal …